IntellaTurn, LLC

Biopharma Research & Information Services

Turning information into intelligence.

  • IntellaTurn is a global consultancy service delivering unbiased and timely business-critical information to biopharma companies and start-ups.

  • We are search engineers trained in source evaluation, bias detection, and information verification of AI outputs.

  • Information becomes intelligence when it is distilled and analyzed.

Get to know our services and subscribe to our free weekly newsletter, “IntellaTurn’s Weekly Scoop,” which delivers headlines impacting the biopharma industry at large.

Read the latest issue below:

IntellaTurn's Weekly Scoop

This week: Regulatory TrendWatch |First-in-class Factor XIa inhibitor| Biotech ‘space race’ | Tracki

‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
IntellaTurn Banner

IntellaTurn's Weekly Scoop

By Erin at IntellaTurn ● Nov 12, 2026

This week: Regulatory TrendWatch |First-in-class Factor XIa inhibitor| Biotech ‘space race’ | Tracking mRNA vaccines

Regulatory TrendWatch

Illustrated collage of a man using binoculars looking directly at the viewer
Source: Axios Visuals

➡️ Committee vote set for Heidi Overton, FDA commissioner nominee

  • The Senate health committee has scheduled a pivotal vote for next week on the nomination of Heidi Overton to serve as commissioner of the FDA — despite lingering doubts from Republicans on the panel.

  • The vote is set for Nov. 18, according to a committee release. If it passes, Overton’s nomination would then go to the full Senate, where Republicans are racing to confirm nominees before Democrats take power in January.

  • Even as he scheduled the vote, committee Chair Bill Cassidy (R-La.) remained undecided on Overton, he wrote in a post on X.

  • It would take just one Republican on the committee to sink her nomination, assuming all Democrats vote against her. (STAT)

➡️ FDA appears to pause controversial speedy review program, CRL disclosures

  • The FDA has quietly shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, a controversial speedy review process launched by former agency head Marty Makary, MD, Reuters reports, citing six sources familiar with the matter, as well as internal documents.

  • Meanwhile, the FDA also appears to have paused publishing complete response letters (CRLs) after briefly halting—and then resuming—the practice in July.

  • The CNPV was designed to accelerate reviews for drugs and companies that support U.S. national interests, such as meeting large unmet medical needs and onshoring of development and manufacturing. The ultra-accelerated process shortens the FDA’s review from the regular 10 months to just one to two months.

  • The pilot’s rollout since June 2025 has been controversial, as public concerns run the gamut from political favoritism and lack of transparency to straining the FDA’s bandwidth. So far, 22 drug programs have received the voucher, with 12 approvals and one rejection to date.

  • The reported pause doesn’t appear to be permanent. In a statement, an HHS spokesperson said work under the CNPV is “ongoing.” At least for programs that have already received a CNPV, the FDA is committed to executing on the promised timeline. (Fierce Pharma)

➡️ FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness

  • The FDA said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden blindness.

  • The condition, called nonarteritic anterior ischemic optic neuropathy, or NAION, affects the optic nerve, which carries signals from the eye to the brain.

  • When blood flow to the nerve is reduced or blocked, it can cause sudden vision loss. The condition is permanent with no known treatment.

  • The FDA said “there is a potential increased risk of rare NAION” in people taking GLP-1 drugs.

  • The agency’s requirement applies to all GLP-1s, including Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, as well as several older GLP-1 diabetes medications. (NBC News)

Notable drug approvals

Sunharbo
Source: Bayer

✅ Bayer’s SUNHARBO: First-in-class drug for reducing the risk of stroke

  • A drug that takes a new approach to preventing blood clots now has FDA approval, introducing a first-in-class factor XIa inhibitor medication for patients who have suffered a stroke.

  • The drug, asundexian, is a treatment for secondary stroke prevention, which is reducing stroke risk following an initial event.

  • The regulatory decision announced late Monday specifically covers adults who have recently had a stroke caused by a clot that did not originate in the heart. It also covers those who have had a high-risk transient ischemic attack, often called a “mini-stroke.”

  • Bayer said its new once once-daily pill will launch in mid-November bearing the brand name Sunharbo. (MedCity News)

✅ Merck KGaA’s PIMJETMI: Daily pill for treatment of rare tumor disorder

  • Merck KGaA secured an FDA approval for its new once-daily oral colony-stimulating factor-1 receptor (CSF-1R) inhibitor, adding to a growing list of regulatory checkmarks around the globe.

  • The agency has approved pimicotinib, under the commercial moniker Pimjetmi, to treat symptomatic tenosynovial giant cell tumor (TGCT), a rare and non-cancerous, locally aggressive tumor that grows in or around the lining of the joints.

  • Pimjetmi is specifically indicated in adults for whom surgical resection of the tumor would cause functional imitation or severe morbidity.

  • The FDA decision hinged on Merck KGaA's phase 3 Maneuver trial and follows similar approvals from regulators in China, Canada and Switzerland. (Fierce Pharma)

BIO pitches US plan to beat China in biotech ‘space race’

Spaceflight launch illustration
Source: Axios Visuals

What’s new: Leaders of the Biotechnology Innovation Organization are calling on the Trump administration to establish a new White House Office of Biotechnology and ease clinical trial requirements in an effort to stem the flow of Chinese innovation that puts American companies at risk.

  • The industry group rolled out the detailed plan on Tuesday to fight back in “our generation’s Space Race,” according to the release.

“If China becomes the world’s biotech leader, it could threaten our national security, cost countless jobs, and leave us dependent on an adversary for life-saving medicines,” BIO CEO John Crowley said in a statement. “Washington policymakers need to act.”

The plan includes seven pillars meant to coordinate a national strategy to boost the American biotech ecosystem, accelerate medical breakthroughs and support future research, manufacturing and intellectual property protections:

BIO action plan
Source: BIO Advance

Continue reading: BioSpace

Interesting read: This woman defied lethal cancer. Can mRNA vaccines make that possible for others?

Illustration of a folder with a question mark cut out of the center.
Source: Axios Visuals

Setting the stage: Donna Gustafson is living a cancer patient's fantasy.

  • At 72, the retired accountant hikes, travels, lifts weights, and exchanges adoring glances with Ed, the husband she married 50 years ago.

  • All these moments are happening while she shows zero evidence of the Stage II pancreatic cancer that was supposed to kill her years ago.

"I have had 100% quality of life; I am back to where I was prior," Gustafson says.

"She's better than that," her husband interjects. "She's sassier, and she's in the best shape of her life — there's no question about that."

What happened: Seven years ago, Gustafson became the world's first recipient of an mRNA vaccine designed to treat pancreatic cancer, a highly lethal disease diagnosed in about 70,000 Americans every year.

  • There are few effective treatments for the disease, but Gustafson's was a personalized version, created using samples of her tumor, aiming to reprogram her immune cells — training them, essentially, to recognize distinctive mutant proteins on cancerous cells and kill them.

mRNA vaccines having a moment: It's been a big year for cancer vaccines using mRNA, especially after drugmakers Merck and Moderna released results last month from the first major successful trial of mRNA vaccines for skin cancer, showing a 42% reduction in recurrence and death over two years.

  • A combination of technologies using mRNA, genomics, and AI helped create these vaccines, which are also being tested on lung, kidney, bladder and brain cancers.

Yes, but: Researchers don't yet understand why some trials have failed, while others show eye-popping results in the form of people like Gustafson.

Continue reading: NPR Health

✨ Thanks for reading! ✨

🌐 About us: IntellaTurn, LLC delivers business-critical and timely information to biopharmaceutical companies and start-ups in the life sciences industry.

📧 Questions? If you liked this, but need more tailored business insights, get in touch about our curated daily, weekly, and bi-weekly newsletters.

IntellaTurn logo

Privacy Policy: IntellaTurn, LLC does not share, rent, or sell your name, email address, or any other information collected on this website.